NCT-506

NCT-506 is an orally bioavailable aldehyde dehydrogenase 1A1 ( ALDH1A1 ) inhibitors with an IC 50 of 7 nM. In Vitro NCT-506 inhibits ALDH1A1, hALDH1A3, hALDH2 with IC 50 s of 0.007±0.001, 16.4±3.99, and 21.5 μM, respectively. NCT-506 (100, 10, 1, 0.1 μM, 6 days) decreases significantly cell viability with an EC 50 of 45.6 μM in OV-90 cells. NCT-506 inhibits MIA PaCa-2, OV-90, and HT-29 cells with IC 50 s of 0.077±0.040, 0.161±0.038, and 0.048±0.022 μM in aldefluor cell-based assays, respectively. NCT-506 is treated in combined with Paclitaxel, IC 50 s of 1202, 924, 870, 411, 102, and 31.8 nM with concentrations of NCT-506 at 0 (DMSO), 1, 3, 10, 20, 30 μM in SKOV-3-TR cells, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: OV-90 and SKOV-3-TR cells Concentration: 100, 10, 1, 0.1 μM Incubation Time: 6 days for OV-90 cells; 4 days for SKOV-3-TR cells Result: Decreased significantly cell viability with an EC 50 of 45.6 μM in OV-90 cells. Decreased cell viability in combined treatments (Paclitaxel concentration of 100 nM) with an EC 50 of 11.2 μM in SKOV-3-TR cells. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet